Impact of Platelet Hyperreactivity and Diabetes Mellitus on Ischemic Stroke Recurrence: A Single-Center Cohort Clinical Study
DOI: https://doi.org/10.2147/ijgm.s450059
IF: 2.145
2024-03-24
International Journal of General Medicine
Abstract:Yusheng Mao, 1, 2 Bangqiang Zhu, 1 Huiqin Wen, 1 Tao Zhong, 1 Maohong Bian 1 1 Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China; 2 Department of Blood Transfusion, The People's Hospital of Chizhou, Chizhou, Anhui Province, People's Republic of China Correspondence: Maohong Bian, Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui Province, 230022, People's Republic of China, Email Purpose: Ischemic stroke recurrence (ISR) is prevented by inhibiting platelet function. To investigate the impact of high on-treatment platelet reactivity (HTPR) assessed by thromboelastography (TEG) and its risk factors on ISR in individuals who have experienced acute ischemic stroke (AIS) receiving dual anti-platelet therapy (DAPT). Patients and Methods: At the end of follow-up, a total of 264 patients who met the criteria were enrolled in this cohort study. The primary endpoint event was a recurrence of ischemic stroke within 90 days of onset. Results: The ISR rate was 7.2% (19/264). The recurrence rate in the HTPR group was 15.1% (8/53), which was significantly higher than the 5.2% (11/211) in the non-HTPR group (p = 0.013), and the type 2 diabetes mellitus (T2DM) group (12.5%, 10/80) was also significantly higher compared to the non-T2DM group (4.9%, 9/184) (p = 0.028). T2DM was an isolated risk factor for HTPR (adjusted OR = 3.06, 95% CI 1.57– 5.98, P = 0.001). Kaplan-Meier plots showed that the cumulative risk (CR) of ISR was statistically different in the HTPR and T2DM groups compared to the non-HTPR group (log-rank P = 0.009) and the non-T2DM group (log-rank P = 0.026), respectively. The HTPR and T2DM groups had greater hazard ratios (HR) of ISR than the non-HTPR (adjusted HR = 2.78, 95% CI 1.06– 7.32, P = 0.038) and non-T2DM (adjusted HR = 2.64, 95% CI 1.01– 6.92, P = 0.049) groups. Conclusion: Both HTPR and T2DM are linked to ISR. Platelet Inhibition Rate (PIR) of TEG can early identify patients who are at high risk for having another ischemic stroke in patients undergoing DAPT, and this study may offer more evidence in favor of clinically personalized treatment and secondary prevention tactics. Keywords: ischemic stroke, diabetes mellitus, clopidogrel, thrombelastography, platelet activation Ischemic stroke recurrence (ISR) is linked to numerous factors, 1,2 including poor antithrombotic effects. The guidelines recommend that patients with noncardioembolic mild ischemic stroke be treated with dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, 3–5 which significantly reduces the rate of ISR. However, studies have shown that ischemic recurrence still occurs in 5–10% of stroke patients in the first three months after receiving DAPT, 6–8 which may be related to platelet reactivity. Laboratory measurements of platelet function below the cut-off value are defined as high on-treatment platelet reactivity (HTPR), which reflects the poor effect of anti-platelet therapy due to individualized differences. According to earlier research in individuals who received DAPT for peripheral arterial disease and coronary artery disease, HTPR is assumed to be brought on by clopidogrel's insufficient platelet inhibition. 9,10 Clopidogrel, a prodrug, is the most widely used P2Y12 receptor antagonist and is bio-transformed in vivo into an active metabolite that irreversibly binds to the platelet adenosine diphosphate (ADP) receptor P2Y12, blocking ADP-induced activation of the GPIIb-IIIa complex and preventing the aggregation of platelets. Individualized differences in clopidogrel are influenced by a variety of factors. 11–13 Nonetheless, the precise mechanisms have not been completely elucidated. Platelet aggregation analyzers currently on the market for detecting the inhibitory effect of clopidogrel on platelet ADP receptors include light transmission aggregometry (LTA) using platelet-rich plasma and multiple electrode aggregometry (MEA), VerifyNow, PL-11/12, and platelet function analyzers (PFA-100/200) using whole blood. 14–17 In recent years, thromboelastography (TEG), which uses ADP-induced accumulation of platelets in vitro to diagnose HTPR to clopidogrel in the laboratory, has begun to be applied to assess the efficacy of clinical anti-thrombotic therapy. The advantage of the TEG over their sole function of detecting platelet aggregation is that it uses whole blood containing clotting factors, platelets, and fibrinogen, which are essential for coagulation, and adds an aggregating agent to mimic in vitro the entire in vivo coagulation-triggere -Abstract Truncated-
medicine, general & internal